DocWire News Editors

DocwireNews

<h1 class="entry-title"><a href="https://www.docwirenews.com/rheumatology/cognitive-decline-may-up-bone-loss-fracture-risk-in-older-women/">Cognitive Decline May Up Bone Loss, Fracture Risk in Older Women</a><p>There is a significant association between cognitive decline and both bone loss and&nbsp;<a href="https://www.docwirenews.com/condition-center/orthopedicscc/orthopedics-center-picks/erythropoietin-hip-fracture/">fracture</a>&nbsp;risk, independent of aging, in community-dwelling, older women, according to a study published online in the&nbsp;<em>Journal of Bone and Mineral Research</em>. The researchers found that the annual percent change in the Mini Mental State Examination (MMSE) was similar for both genders (women, &minus;0.33; men, &minus;0.34). However, after multivariable adjustment, cognitive decline was associated with bone loss in women (6.5 percent for each percent decline in MMSE from baseline), but not men. By year five, approximately 13 percent of participants experienced significant cognitive decline. In addition, there was a significant increase in fracture risk among women (multivariable hazard ratio, 1.61). &ldquo;These findings may help refine clinical practices guidelines regarding how bone loss and cognitive decline can be monitored in older age, to ensure appropriate and effective treatment,&rdquo; Bliuc said in a statement.</p><h1 class="entry-title"><a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/fluorescence-optical-imaging-is-able-to-effectively-discriminate-between-rheumatoid-arthritis-patients-with-and-without-need-of-rituximab-retherapy/">Fluorescence Optical Imaging Discriminates Between Rheumatoid Arthritis Patients With and Without Rituximab Retherapy</a></h1><p>A study shows that fluorescence optical imaging (FOI) can successfully discriminate between <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/women-may-avoid-arthritis-treatment-due-to-pregnancy-and-lactation-concerns/">rheumatoid arthritis</a> patients with and without the need for rituximab (RTX) retherapy. The findings were <a href="https://pubmed.ncbi.nlm.nih.gov/34344678/" target="_blank" rel="nofollow noopener noreferrer">published in</a>&nbsp;<em>BMJ Open. </em>To conduct this analysis, 31 patients with established RA were prospectively followed over one year and assessed for the following parameters: Disease Activity Score 28, global disease activity (visual analogue scale 0-100 mm), C reactive protein and erythrocyte sedimentation rate, ultrasound seven joint (US7) score and FOI in phases 1-3 and automatically generated PrimaVista mode (PVM) at baseline (before RTX) and after 3, 6 and 12 months. The need for RTX retherapy was decided by the treating rheumatologist-blinded to imaging data, the researchers noted. Overall, 45.2% of patients received RTX retherapy within 12 months. Furthermore, in the group that underwent RTX retherapy, FOI in PVM mode was the only parameter that markedly (&beta;: 0.40, 95% CI: 0.08 to 0.71, p=0.013)-compared with the group without retherapy. &ldquo;US7 GS synovitis score and FOI in PVM are able to discriminate between patients with and without need for RTX retherapy better than clinical and laboratory parameters,&rdquo; the researchers wrote in conclusion.</p><p>&nbsp;</p></h1>


Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Rheumatology Round-up: Cognitive Decline Ups Bone Fracture Risk, and More

Rheumatology

Cognitive Decline May Up Bone Loss, Fracture Risk in Older Women ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe